Ftse Mib
34.181,42
-0,56%
DAX
19.955,55
-0,24%
S&P 500
5.868,55
-0,22%
NASDAQ
19.280,79
-0,16%
Bitcoin
96.193,15
-0,73%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Xencor Inc (XNCR) Xencor Inc (XNCR) Notizie

XNCR

Xencor (XNCR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XNCR
DataOraFonteTitoloSimboloCompagnia
26/11/202422:01Business WireXencor to Participate at Upcoming Investor ConferencesNASDAQ:XNCRXencor Inc
21/11/202422:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XNCRXencor Inc
15/11/202400:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XNCRXencor Inc
15/11/202400:16Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:XNCRXencor Inc
06/11/202422:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XNCRXencor Inc
06/11/202422:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XNCRXencor Inc
06/11/202422:01Business WireXencor Reports Third Quarter 2024 Financial ResultsNASDAQ:XNCRXencor Inc
04/11/202413:00Business WireXencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel DiseaseNASDAQ:XNCRXencor Inc
21/10/202422:18Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:XNCRXencor Inc
10/10/202414:09Business WireXencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel DiseasesNASDAQ:XNCRXencor Inc
04/10/202414:01Business WireXencor Announces Upcoming Change to Board of DirectorsNASDAQ:XNCRXencor Inc
12/09/202422:01Business WireXencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:XNCRXencor Inc
12/09/202414:45Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:XNCRXencor Inc
11/09/202412:31Business WireXencor Announces Pricing of $175 Million Public Offering of Common StockNASDAQ:XNCRXencor Inc
10/09/202422:01Business WireXencor Announces Proposed Public Offering of Common StockNASDAQ:XNCRXencor Inc
09/09/202413:31Business WireXencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology ProgramsNASDAQ:XNCRXencor Inc
06/09/202414:01Business WireXencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024NASDAQ:XNCRXencor Inc
05/08/202422:01Business WireXencor Reports Second Quarter 2024 Financial ResultsNASDAQ:XNCRXencor Inc
13/06/202414:01Business WireXencor Regains CD20 x CD3 Bispecific T-Cell EngagerNASDAQ:XNCRXencor Inc
09/05/202422:09Business WireXencor Reports First Quarter 2024 Financial ResultsNASDAQ:XNCRXencor Inc
09/04/202414:01Business WireXencor Appoints Bart Cornelissen as Chief Financial OfficerNASDAQ:XNCRXencor Inc
28/02/202422:01Business WireXencor to Present at Upcoming Investor ConferencesNASDAQ:XNCRXencor Inc
27/02/202422:01Business WireXencor Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:XNCRXencor Inc
20/02/202422:31Business WireXencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical UpdateNASDAQ:XNCRXencor Inc
16/02/202423:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XNCRXencor Inc
03/01/202422:01Business WireXencor to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:XNCRXencor Inc
02/01/202414:01Business WireDane Leone Joins Xencor as Senior Vice President, Corporate StrategyNASDAQ:XNCRXencor Inc
21/11/202322:01Business WireXencor to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:XNCRXencor Inc
07/11/202322:01Business WireXencor Reports Third Quarter 2023 Financial ResultsNASDAQ:XNCRXencor Inc
07/11/202322:01Business WireXencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 MillionNASDAQ:XNCRXencor Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XNCR

La tua Cronologia

BINA
COSUSDT
Contentos
SUSHI
NXLETH
Next Level
AQSE
SPY5.GB
SPDR S&P 500 UCITS ETF
BIT
P1MB88
BNP Paribas Issuance
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network